Rockwood Announces Advancements in Strategic Planning
Rockwood Capital, LLC (“Rockwood”), a private real estate investment management firm, today announced that Peter Falco, Senior Managing Partner and a co-founder, will transition to the role of Senior Strategic Advisor beginning in January 2018. Consistent with the firm’s succession planning, Walter Schmidt, Senior Managing Partner and a co-founder, Tyson Skillings, Managing Partner, and Peter Kaye, Managing Partner, the other current members of the firm’s Management Committee, will remain in their current management roles with the continued support of the firm’s other partners: Bob Gray, a co-founder, David Becker, Tony Lariño and David Streicher. Messrs. Schmidt, Skillings and Kaye have been with Rockwood, including its predecessors, for 31, 15, and 15 years, respectively.
In addition to firm management, Mr. Falco has held leadership positions in client strategies, portfolio management and debt capital markets. In his new role, he will advise the firm with respect to client strategies, trends in global capital flows and policy initiatives that impact domestic real estate investment. Mr. Skillings will assume oversight of the client outreach efforts previously coordinated by Mr. Falco.
“My transition to Senior Strategic Advisor is part of a succession plan that Rockwood set in motion many years ago to ensure that the firm would remain well positioned to deliver outstanding performance to our investors over many years and investment cycles,” Falco said. “I have unwavering confidence in the management team and the ‘best in class’ investment professionals who are supporting them.”
“While we continue to evolve our organization to meet the needs of our clients over the long term, the central tenets of our investment philosophy have been in place for decades,” Schmidt added.
In addition, as part of the firm’s ongoing strategic planning, Rockwood has hired Alexia Gottschalch as a Managing Director and Global Head of Client Strategy. She will report to Mr. Skillings and be based in the New York office.
Ms. Gottschalch comes to Rockwood from J.P. Morgan Asset Management – Global Real Assets, where she was Head of Business Development and Client Strategy, Real Estate Americas. In that role, she led a team of eight client portfolio managers and was responsible for executing a capital strategy for the $70 billion real estate platform. Prior to that, Ms. Gottschalch held senior positions with Grosvenor, PGIM, Tishman Speyer and ING.
“We are very excited that Alexia has agreed to join the team,” Skillings said. “She is an accomplished real estate professional who brings tremendous experience and enthusiasm to the role. She shares our commitment to outstanding client service.”
About Rockwood Capital
Rockwood Capital, LLC (Rockwood), founded in 1995, is a closely-held, independently managed real estate investment management firm. It provides equity capital combined with real estate operating expertise for the repositioning, recapitalization, development and redevelopment of residential, office, research and development, retail and hotel space in select markets throughout the United States. Rockwood and its principals have invested on behalf of their clients approximately $26.6 billion of real estate through ten value-add vehicles and eight separate accounts. Today, Rockwood is a 78-person organization with offices in New York, NY, San Francisco, CA and Los Angeles, CA that manages a portfolio of approximately $3.5 billion of net equity value in approximately $9.4 billion of gross real estate value. Rockwood’s investors include public and private pension funds, endowments, foundations, insurance companies, fund of funds, high net worth individuals and family offices.
Owen Blicksilver Public Relations, Inc.
Caroline Luz, 203-656-2829
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F24.4.2018 20:30 | Pressemelding
Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2017 “Document de Référence” for the year ended December 31, 2017, including the management report and the annual financial report with the “Autorité des Marchés Financiers (AMF)” and its Annual Report on Form 20-F for the year ended December 31, 2017 with the U.S. Securities and Exchange Commission (SEC). These documents can be accessed on the Investors section of the Company’s corporate website (www.erytech.com). In addition, the “Document de Référence” is also available on the AMF’s website (http://www.amf-france.org) and the Annual Report on Form 20-F is also available on the SEC’s website (www.sec.gov). Printed copies of these documents are also
Rimini Street Launches New Solutions that Further Extend the Life and Value of Enterprise Software as a Foundation for Innovation24.4.2018 16:00 | Pressemelding
Rimini Street, Inc . (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the first offerings in a family of solutions designed to provide improved competitive advantage to organizations with mature and valuable enterprise software investments that can be used as a foundation for innovation. Rimini Street’s new solutions can enable an organization to quickly and cost-effectively modernize their current enterprise software with the latest desired features and capabilities, future-proof their technical platforms against yet-unknown technology changes, and secure their systems against a constantly evolving threat environment. Rimini Street’s new solutions enable organizations to leverage their existing systems as a solid foundation for an innovative hybrid IT strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/
Novaliq to Present Scientific and Clinical Research During the 2018 Association for Research in Vision and Ophthalmology Meeting in Honolulu, HI24.4.2018 15:53 | Pressemelding
Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Meeting in Honolulu, HI (April 29-May 3). The variety of data to be presented reflects Novaliq’s dedication to science and clinical research. With the collection of posters, Novaliq will share clinical and pre-clinical data on its EyeSol® drug delivery technology and provide insights into the mode of action of its NOV03/NovaTears® water-free therapy for the treatment of dry eye disease (DED). Furthermore, Novaliq will present its first pre-clinical efficacy data in glaucoma. Scientific posters supported by Novaliq will include: “Influence of perfluorohexyloctane containing eye drops on tear film thickness in patients with mild to moderate dry eye disease.” Authors: Garhöfer G., Schm
Temasys Communications and Appian Partner to Power Real-Time Communications in the Contact Center24.4.2018 15:00 | Pressemelding
Temasys Communications announced today that Appian has integrated with the Temasys Skylink technology, enabling real-time communications, including chat and co-browsing, in Appian’s new Intelligent Contact Center (ICC) Platform. “For our contact center customers, omni-channel communications are essential. Appian is working with Temasys to provide contact centers with real-time communication channels such as chat and co-browsing via the Temasys versatile SDKs,” said Arturo Oliver, Senior Director of Product Strategy at Appian. Temasys Skylink APIs will be compatible with the Appian Intelligent Contact Center Platform, making it easy for Appian customers to add real-time communication to their applications, including chat, voice, video and co-browsing. These integrations enable users to visit a website, begin a chat session that seamlessly escalates to a voice call and extend to co-browsing — all without changing apps or establishing a new connection. “We’re thrilled to work with Appian
PPG Reports Sustainability Progress, New 2025 Goals24.4.2018 13:07 | Pressemelding
PPG (NYSE:PPG) today released its 2017 Corporate Sustainability Report, which details the company’s continued progress in strengthening its sustainable operations in 2017 and the launch of new, aggressive sustainability goals it aims to achieve by 2025. The report is available at sustainability.ppg.com. “PPG’s sustainability efforts go beyond product innovations to extend to our customers’ operations and the communities in which we operate,” said Mark Cancilla, PPG vice president, environment, health and safety. “We are encouraged by our progress in 2017 and excited about our new goals, which are representative of the challenges and opportunities of our current business portfolio.” The company achieved the following progress in 2017: 32 percent of sales from products that provide customers with a sustainable advantage, an increase of 60 percent since 2012. This includes the unveiling of multiple products that provide a sustainable solution, such as Sigma Air Pure, a revolutionary bio-b
Bioiberica Approves Its Combined Drug for Osteoarthritis in Five More European Countries24.4.2018 12:17 | Pressemelding
Bioiberica's combination of chondroitin sulphate and glucosamine hydrochloride, a slow action drug to treat osteoarthritis symptoms, was approved as an ethical drug in France, Austria, Hungary, Poland, and Finland through a mutual recognition process from Spain. ‘This approval confirms that Drug Agencies from different countries attest to the effectiveness and safety of the combination of pharmaceutical grade chondroitin sulphate and glucosamine hydrochloride. This drug has proven to reduce pain and improve mobility in people affected by knee osteoarthritis which, due to its safety profile, could also be used as an alternative by those patients with cardiovascular or gastrointestinal problems who should not be prescribed anti-inflammatory drugs chronically’, stated Dr Juan Gispert, Bioiberica's R&D director. The principle study that guarantees its effectiveness is the MOVES clinical trial, published in the Annals of the Rheumatic Diseases, which concludes that the combination of chondr